Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Amicus Therapeutics reports strong Q1 performance and growth opportunities

Amicus Therapeutics delivered strong Q1 2024 results, driven by Galafold's performance and a focus on expanding patient numbers for Pombiliti and Opfolda.
While facing challenges such as increased operating expenses and potential manufacturing issues, the company remains confident in its growth trajectory and supply capabilities.
Opportunities lie in revenue expansion, leveraging positive feedback for Pombiliti and Opfolda, and enhancing real-world evidence generation through registries.
Efforts to streamline treatment processes and establish new standards of care position Amicus for continued growth and impact in the rare disease space.

Amicus Therapeutics (FOLD) reports robust Q3 earnings and growth strategies

Amicus Therapeutics (FOLD) delivered strong financial performance in Q3 2024, driven by robust Galafold revenue and strategic focus on patient access.
While facing competitive pressures and regulatory challenges, the company aims to sustain growth through pipeline development and expense management.
Raising financial guidance and exploring accelerated approval opportunities position Amicus for continued success in the genetic medicine market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Investors cheered an analyst's upgrade of the biotech stock.

Why Amicus Therapeutics Stock Is Soaring Today

Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.

Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold

Carnival

Royal Caribbean Cruises

Bank of Montreal

Dicerna Pharmaceuticals

Golar LNG

Switch

Truecar Inc

With the trading day more than halfway over, the broad markets pulled back from their impressive start to the week.

Carnival, Royal Caribbean, Switch and More Tuesday Afternoon Analyst Calls

Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2020 Results - Earnings Call Transcript

Shares of Amicus Therapeutics (NASDAQ:FOLD) moved higher by 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.86% over the past year to ($0.27), which missed the estimate of ($0.23).

Amicus Therapeutics: Q4 Earnings Insights

Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutics's Q4 earnings.

Earnings Preview for Amicus Therapeutics

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.

Why This Rare-Disease Biotech Stock Just Lost A Third Of Its Value

Amicus Stock Plunges After Rare-Disease Drug Misses In Key Study

Shares of Amicus Therapeutics Inc. were down 23.1% in premarket trading on Friday, the day after the company said an experimental rare disease drug failed to perform better than the standard of care in a late-stage trial. The investigational drug, AT-GAA, is a treatment for Pompe disease, a rare, genetic disease that causes severe muscle weakness.

SVB Leerink, J.P. Morgan downgrade Amicus stock after Phase 3 data for rare disease drug comes out

Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021

Amicus' AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study

Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease

Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses

Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021

Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.

Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options

CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that three oral presentations and ten posters highlighting its development programs for Lysosomal Disorders will be included at the 17th Annual WORLDSymposium™ 2021, to be held virtually February 8-12, 2021.

Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021

CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference, being held virtually on Tuesday, January 12, 2021 at 8:20 a.m. ET.

Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ: SRPT) render their stocks as top picks for the first half of 2021, according to an analyst at BofA Securities.

Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.1%

CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been nationally recognized as a Great Place to Work-Certified™ Company in 2020. Great Place to Work® is the global authority on workplace culture, employee experience and leadership behaviors proven to deliver market-leading revenue and increased innovation. This Certification utilizes validated employee feedback based on the Great Place to Work's data driven methodology and indicates that Amicus employees consistently acknowledge a positive work experience and value the overall corporate culture of the company.

Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Up 8.6% Since Last Earnings Report?

Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.

Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA

On Track for Completing the BLA Submission in 1H2021

Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease

The shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)  are up 1.3% at $22.69 at last check, after hitting a Nov. 18, all-time-high of $23.19.

FOLD Could Soon Conquer New Record High, Bull Signal Suggests

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2020 at 2:15 p.m. E.T.

Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.

News for Amicus Therapeutics Stock (FOLD)